BioMarin announced on the 14th June 2018, the first administration of BMN 111 to young children with achondroplasia under 5 years old. (1) This is the BMN 111-206 study, a phase 2 study in Infants and Toddlers. What … Continue reading
June 30, 2018
by inesp.alves
3 Comments